E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary Raynaud's Phenomenon and Systemic Sclerosis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042953 |
E.1.2 | Term | Systemic Sclerosis |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037917 |
E.1.2 | Term | Raynaud's phenomenon |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
An explorative study investigating the potential therapeutic effects of asasantin retard in patients with primary Raynaud's phenomenon and systemic sclerosis through assessment of treatment effects on: 1) the clinical severity of Raynaud's phenomenon 2) the finger blood flow response to cold stress test (assessed using thermal and laser speckle imaging) 3) Platelet function testing assessed using aggregometry 4) blood markers of platelet activation and endothelial damage 5) level of oxidative stress
|
|
E.2.2 | Secondary objectives of the trial |
1) Assessment of the reproducibility of the cold challenge test assessed using thermal imaging and laser contrast speckle imaging in patients with primary Raynaud's phenomenon and systemic sclerosis.
2) Assessment of the "validity" of a series of biomarkers of platelet activation and aggregometry in predicting subtype and severity of disease, in patients with primary Raynaud's phenomenon and systemic sclerosis i.e. do levels of these markers correlate with disease type and severity in patients with Raynaud's phenomenon and systemic sclerosis.
3) Comparison between platelet function in PRP vs SSc and response to asasantin retard therapy.
4) Assessment of markers of oxidative stress in patients with primary Raynaud's and systemic sclerosis and the potential therpeutic effects of asasantin retard therapy |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Systemic Sclerosis (fulfilling ARA criteria)
or
Primary Raynaud's Phenomenon (defined as at least 2 episodes of fingertip localized notable blue and/or sequential blue and white discoloration, in conjunction with pain upon cold exposure or emotional stress within the one week of examination in the absence of other features of connective tissue disease.
18 to 75 years of age
|
|
E.4 | Principal exclusion criteria |
Subjects shall be excluded from all aspects of the study if:
1) pregnant or breastfeeding (women of child bearing age will be required to practice a medically acceptable method of birth control throughout the study period)
2) surgical sympathectomy performed in the last 12 months
3) Administration of new medications used for the treatment of Raynaud's phenomenon or systemic sclerosis in the 2 months preceding, or during, the trial period.
4) Vasodilators used for the treatment of hypertension must be maintained at a constant dose throughout the study period.
5) Administration of a selective serotonin reuptake inhibitor in the 2 months preceding or during the study period.
6) Refusal by participants for their General Practitioner to be informed of inclusion in the study
Subjects shall remain eligible for the first part of the study but shall be excluded from participation in the second stage of the study if they are:
1) current use of aspirin, dipyridamole or alternative antiplatelet agent
2) primary bleeding diathesis or platelet disorder
3) anticoagulation with warfarin
4) history of peptic or duodenal ulceration
5) history of intolerance or allergy to aspirin, dipyridamole or other nonsteroidal anti-inflammatory medications
6) Current use of oral corticosteroids and/or non-steroidal anti-inflammatory drugs
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The Raynaud's Condition Score (RCS) in patients with primary Raynaud's phenomenon and systemic sclerosis, before and during 2 weeks treatment with asasantin retard. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
No treatment run-in phase. |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be defined as the last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |